Avid Bioservices (STU:TEHN) Total Liabilities : €255.8 Mil (As of Oct. 2024)

View and export this data going back to . Start your Free Trial

What is Avid Bioservices Total Liabilities?

Avid Bioservices's Total Liabilities for the quarter that ended in Oct. 2024 was €255.8 Mil.

Avid Bioservices's quarterly Total Liabilities declined from Apr. 2024 (€256.92 Mil) to Jul. 2024 (€254.48 Mil) but then increased from Jul. 2024 (€254.48 Mil) to Oct. 2024 (€255.82 Mil).

Avid Bioservices's annual Total Liabilities increased from Apr. 2022 (€236.42 Mil) to Apr. 2023 (€239.31 Mil) and increased from Apr. 2023 (€239.31 Mil) to Apr. 2024 (€256.92 Mil).

Avid Bioservices Total Liabilities Historical Data

The historical data trend for Avid Bioservices's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices Total Liabilities Chart

Avid Bioservices Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Total Liabilities

Get a 7-Day Free Trial

60.47

156.98

236.42

239.31

256.92

Avid Bioservices Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
Total Liabilities	Get a 7-Day Free Trial															256.61	252.50	256.92	254.48	255.82

Avid Bioservices Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Avid Bioservices's Total Liabilities for the fiscal year that ended in Apr. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	65.768	+	(191.088	+	7.2719608112948E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0.067	+	0	+	0)
	=	256.9

Total Liabilities	=	Total Assets (A: Apr. 2024 )	-	Total Equity (A: Apr. 2024 )
	=	313.671	-	56.749
	=	256.9

Avid Bioservices's Total Liabilities for the quarter that ended in Oct. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	68.075	+	(187.346	+	0.40199999999999
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	255.8

Total Liabilities	=	Total Assets (Q: Oct. 2024 )	-	Total Equity (Q: Oct. 2024 )
	=	296.956	-	41.134
	=	255.8

Avid Bioservices Total Liabilities Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Avid Bioservices Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (STU:TEHN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

14191 Myford Road, Tustin, CA, USA, 92780

Website

https://www.avidbio.com

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.

Avid Bioservices Headlines

No Headlines